Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).

about

Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report.

P2860

Q48192635-B329BD13-FD14-4585-81AE-5358D986C59F

P2860

Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).

Item

http://www.wikidata.org/entity/Q38856226

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Small molecules and antibodies ...... : a patent review (2010-2015).

@en

type

Item

label

Small molecules and antibodies ...... : a patent review (2010-2015).

@en

prefLabel

Small molecules and antibodies ...... : a patent review (2010-2015).

@en

P1476

Small molecules and antibodies ...... s: a patent review (2010-2015)

@en

P2093

Andrea Chiricozzi

http://www.w3.org/2001/XMLSchema#string

Lucia Novelli

http://www.w3.org/2001/XMLSchema#string

Maria Sole Chimenti

http://www.w3.org/2001/XMLSchema#string

Monika Fida

http://www.w3.org/2001/XMLSchema#string

Roberto Perricone

http://www.w3.org/2001/XMLSchema#string

Rosita Saraceno

http://www.w3.org/2001/XMLSchema#string

Sergio Chimenti

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis

Jaks and STATs: biological implications

Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency.

Engineered protein scaffolds as next-generation antibody therapeutics.

Engineering novel binding proteins from nonimmunoglobulin domains.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial.

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation.

P304

757-766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543776.2016.1192129

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27266423

http://www.w3.org/2001/XMLSchema#string

Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).

about

P2860

P2860

Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698